20hon MSN
We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...
We recently published a list of 13 High Growth Large Cap Stocks To Invest In. In this article, we are going to take a look at ...
In a regulatory filing, Vertex Pharmaceuticals (VRTX) chief scientific officer David Altshuler disclosed the sale of 3,231 common shares of the ...
Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 5 years ago, it would be worth $253.80 today based on a ...
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a ...
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX). But which of these two stocks ...
Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...
Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and Alyftrek launch progress. Fear, uncertainty, and doubt have become the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results